Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 25,218	$ 198,955
Short-term investments	708,737	862,941
Accounts receivable	22,492	38,889
Inventory	15,801	15,292
Other current assets	23,333	21,928
Total current assets	795,581	1,138,005
Long-term investments	64,828	136,662
Property, plant and equipment, net	60,510	59,662
Operating lease right-of-use assets	117,025	126,476
Goodwill	76,501	76,501
Other assets	2,744	1,461
Total assets	1,117,189	1,538,767
Current liabilities:
Accounts payable	9,747	22,139
Accrued compensation	15,735	14,532
Accrued clinical trial expenses	26,809	44,207
Other accrued expenses	15,468	20,986
Operating lease liabilities, current portion	17,441	13,915
Total current liabilities	85,200	115,779
Operating lease liabilities, less current portion	125,736	136,373
Development derivative liability	27,726	0
Liabilities related to the sales of future royalties, net	195,427	200,340
Other long-term liabilities	3,592	8,980
Total liabilities	437,681	461,472
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated, issued or outstanding at December 31, 2021 or 2020	0	0
Common stock, $0.0001 par value; 300,000 shares authorized; 185,468 shares and 180,091 shares issued and outstanding at December 31, 2021 and 2020, respectively	19	18
Capital in excess of par value	3,516,641	3,388,730
Accumulated other comprehensive loss	(4,157)	(2,295)
Accumulated deficit	(2,832,995)	(2,309,158)
Total stockholders’ equity	679,508	1,077,295
Total liabilities and stockholders’ equity	$ 1,117,189	$ 1,538,767